CA2881389C - Methods and kits for screening patients with a cancer - Google Patents

Methods and kits for screening patients with a cancer Download PDF

Info

Publication number
CA2881389C
CA2881389C CA2881389A CA2881389A CA2881389C CA 2881389 C CA2881389 C CA 2881389C CA 2881389 A CA2881389 A CA 2881389A CA 2881389 A CA2881389 A CA 2881389A CA 2881389 C CA2881389 C CA 2881389C
Authority
CA
Canada
Prior art keywords
cancer
patient
predetermined reference
patients
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2881389A
Other languages
English (en)
French (fr)
Other versions
CA2881389A1 (en
Inventor
Jerome Galon
Franck Pages
Bernhard Mlecnik
Gabriela BINDEA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Paris filed Critical Assistance Publique Hopitaux de Paris APHP
Publication of CA2881389A1 publication Critical patent/CA2881389A1/en
Application granted granted Critical
Publication of CA2881389C publication Critical patent/CA2881389C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CA2881389A 2012-08-06 2013-08-05 Methods and kits for screening patients with a cancer Active CA2881389C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305975 2012-08-06
EP12305975.0 2012-08-06
PCT/EP2013/066425 WO2014023706A1 (en) 2012-08-06 2013-08-05 Methods and kits for screening patients with a cancer

Publications (2)

Publication Number Publication Date
CA2881389A1 CA2881389A1 (en) 2014-02-13
CA2881389C true CA2881389C (en) 2022-01-04

Family

ID=46762994

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2881389A Active CA2881389C (en) 2012-08-06 2013-08-05 Methods and kits for screening patients with a cancer

Country Status (13)

Country Link
US (2) US20150218650A1 (https=)
EP (2) EP2880180B1 (https=)
JP (2) JP6559566B2 (https=)
AU (1) AU2013301609B2 (https=)
CA (1) CA2881389C (https=)
DK (1) DK2880180T3 (https=)
ES (1) ES2702722T3 (https=)
LT (1) LT2880180T (https=)
PL (1) PL2880180T3 (https=)
PT (1) PT2880180T (https=)
SG (1) SG11201500922RA (https=)
TR (1) TR201819211T4 (https=)
WO (1) WO2014023706A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
KR20170042778A (ko) * 2014-08-19 2017-04-19 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 면역 세포의 기능 증강 방법 및 면역 세포의 다기능성 평가 방법
JP2018503373A (ja) * 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
EP3455631B1 (en) * 2016-05-09 2020-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for classifying patients with a solid cancer
TW201837467A (zh) 2017-03-01 2018-10-16 美商建南德克公司 用於癌症之診斷及治療方法
JP6565093B1 (ja) 2018-03-22 2019-08-28 住友電工ハードメタル株式会社 表面被覆切削工具およびその製造方法
WO2020072223A1 (en) * 2018-10-01 2020-04-09 Nantomics, Llc Evidence based selection of patients for clinical trials using histopathology
SG11202112712RA (en) 2019-06-03 2021-12-30 Inst Nat Sante Rech Med Methods for modulating a treatment regimen
WO2021092071A1 (en) 2019-11-07 2021-05-14 Oncxerna Therapeutics, Inc. Classification of tumor microenvironments
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
EP4172628A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
US20230235408A1 (en) 2020-06-30 2023-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
US20250035635A1 (en) 2022-03-17 2025-01-30 Institut National De La Sante Et De La Recherche Medicale Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888278A (en) 1985-10-22 1989-12-19 University Of Massachusetts Medical Center In-situ hybridization to detect nucleic acid sequences in morphologically intact cells
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US6280929B1 (en) 1986-01-16 2001-08-28 The Regents Of The University Of California Method of detecting genetic translocations identified with chromosomal abnormalities
US5427932A (en) 1991-04-09 1995-06-27 Reagents Of The University Of California Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using
US5472842A (en) 1993-10-06 1995-12-05 The Regents Of The University Of California Detection of amplified or deleted chromosomal regions
US6942970B2 (en) 2000-09-14 2005-09-13 Zymed Laboratories, Inc. Identifying subjects suitable for topoisomerase II inhibitor treatment
JP2002363169A (ja) * 2001-06-08 2002-12-18 Fujiyakuhin Co Ltd 抗腫瘍活性を有する複素環化合物
US20110152115A1 (en) * 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
EP1664762A4 (en) * 2003-09-03 2008-08-13 Us Gov Health & Human Serv METHOD OF IDENTIFYING AND DIAGNOSIS OF, AND VIEWING, SURVIVAL IN LYMPHOMA
CA2606018A1 (en) 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Nanoparticle conjugates
CA2609702C (en) 2005-04-28 2013-05-28 Ventana Medical Systems, Inc. Antibody conjugates via heterobifunctional peg linkers
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US20070117153A1 (en) 2005-11-23 2007-05-24 Christopher Bieniarz Molecular conjugate
US20110070582A1 (en) * 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
PL2619576T3 (pl) * 2010-09-24 2021-07-05 Niels Grabe Środki i sposoby do prognozowania odpowiedzi na leczenie u pacjenta chorego na nowotwór złośliwy
US20140018255A1 (en) * 2011-01-11 2014-01-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for predicting the outcome of a cancer in a patient by analysing gene expression

Also Published As

Publication number Publication date
JP2015530877A (ja) 2015-10-29
AU2013301609B2 (en) 2019-03-14
TR201819211T4 (tr) 2019-01-21
WO2014023706A1 (en) 2014-02-13
DK2880180T3 (en) 2019-01-14
US20150218650A1 (en) 2015-08-06
EP3470531A1 (en) 2019-04-17
JP6559566B2 (ja) 2019-08-14
ES2702722T3 (es) 2019-03-05
AU2013301609A1 (en) 2015-02-26
LT2880180T (lt) 2019-01-25
SG11201500922RA (en) 2015-04-29
JP2019176880A (ja) 2019-10-17
PL2880180T3 (pl) 2019-04-30
JP6995091B2 (ja) 2022-01-14
CA2881389A1 (en) 2014-02-13
EP2880180A1 (en) 2015-06-10
PT2880180T (pt) 2018-12-27
EP2880180B1 (en) 2018-10-03
US20200299784A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
CA2881389C (en) Methods and kits for screening patients with a cancer
HK1208624A1 (en) Methods for treating or predicting risk of a ventricular tachyarrhythmia event
WO2017049251A3 (en) Therapeutic cd47 antibodies
JP2015530877A5 (https=)
WO2018074758A3 (ko) 면역질환 치료를 위한 고효능 줄기세포 선별방법
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
MX2021009297A (es) Composiciones, dispositivos, y metodos de pruebas de sensibilidad del ibs.
EP4585701A3 (en) Methods and materials for assessing homologous recombination deficiency
NZ621733A (en) Lung cancer biomarkers and uses thereof
EP4524569A3 (en) Methods, compositions and devices for treating cancer with illudofulvenes
GB2427468A (en) Devices and methods for enrichment and alteration of circulating tumour cells and other particles
WO2011135194A3 (en) Method for diagnosing risk of type 1 diabetes and for preventing onset of type 1 diabetes
EP3791944A3 (en) Water ride
WO2014081944A9 (en) Egfr and c-met-fibronectin type iii domain binding molecules
WO2020198370A3 (en) Therapeutic cd47 antibodies
WO2018183817A3 (en) Tumor burden as measured by cell free dna
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
ZA202206807B (en) Genotype stratification in diabetes treatment and prevention
WO2015153997A3 (en) Notch3 antibodies and uses thereof
WO2015085314A3 (en) Methods for detection of heart failure
MX2023005293A (es) Composiciones, dispositivos y metodos de prueba de sensibilidad a la depresion.
WO2005058251A3 (en) Hla-dr-specific antibodies, compositions and methods
WO2014179737A3 (en) Assays and methods of treatment relating to vitamin d insufficiency
MX2023006660A (es) Composiciones, dispositivos, y metodos de pruebas de sensibilidad a la osteoartritis.
GB2552271A (en) A method for diagnosing lung cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180718

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251212

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260326